Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Compared for Type 2 Diabetes Remission Mechanisms
Background
While Type 2 Diabetes often improves or resolves in up to 80% of patients after bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), a significant number experience no remission despite substantial weight loss. This variability suggests that factors beyond mere weight reduction, such as changes in incretin function, insulin production, and insulin sensitivity, play a crucial role. Understanding these differential physiological responses to various surgical procedures is essential to predict outcomes and develop more targeted interventions for Type 2 Diabetes management.
Study Design
This proposed study will enroll 75 adults undergoing bariatric surgery at Mayo Clinic Rochester. 25 participants will receive Roux-en-Y Gastric Bypass (RYGB), while 50 will undergo Sleeve Gastrectomy (SG). The study aims to describe the effects of these procedures on incretin levels, insulin production, and insulin sensitivity. Researchers will compare these metabolic parameters between patients who achieve Type 2 Diabetes remission and those who do not, seeking to identify factors influencing surgical outcomes.
Results
This record describes a study protocol, not a completed research paper. Therefore, no findings are available yet. The study aims to investigate the mechanisms underlying variable Type 2 Diabetes remission rates following bariatric surgery, specifically comparing Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG). Researchers will analyze changes in incretin levels, insulin production, and insulin sensitivity to identify factors contributing to diabetes recovery or persistence post-surgery. The primary goal is to provide a detailed description of these physiological effects and compare outcomes between patients who achieve diabetes remission and those who do not. This will help elucidate why some patients experience profound metabolic improvements while others do not. > The study's core objective is to identify specific physiological markers that differentiate between successful and unsuccessful Type 2 Diabetes remission post-bariatric surgery.
Key Findings
- To compare incretin, insulin production, and sensitivity changes after RYGB vs. SG.
- To identify factors affecting Type 2 Diabetes remission post-bariatric surgery.
- To describe physiological effects of bariatric surgery on metabolic parameters.
Why It Matters
Understanding the specific mechanisms driving Type 2 Diabetes remission after bariatric surgery is critical for refining patient selection and personalizing treatment strategies. If distinct incretin or insulin profiles can predict remission, clinicians could better guide patients toward the most effective surgical option or adjunctive therapies. This research could inform the development of novel pharmacological interventions that mimic the beneficial metabolic effects of surgery, offering alternatives for patients unsuitable for bariatric procedures. Furthermore, findings might highlight specific physiological targets for optimizing post-surgical care or for combination with new anti-obesity medications like semaglutide or tirzepatide, which also modulate incretin pathways, potentially leading to more predictable and effective outcomes.
bariatric surgery
type 2 diabetes
diabetes remission
roux-en-y gastric bypass
sleeve gastrectomy
incretins